Introduction: Linagliptin is a xanthine-based
INTRODUCTION
Dipeptidyl peptidase (DPP)-4 inhibitors are oral antidiabetic agents that act by inhibiting the degradation of the gastrointestinal incretin hormones, glucagon-like peptide (GLP)-1 and glucose-dependent insulinotropic polypeptide (GIP), by the DPP-4 enzyme [1, 2] . The resulting increase in availability of these hormones stimulates glucose-dependent insulin release from pancreatic beta cells, while reducing glucagon output from pancreatic alpha cells [3] .
Although there is no consensus on the best choice of antihyperglycemic agent for patients in whom metformin fails to maintain glycemic control, it has been suggested that the addition of a DPP-4 inhibitor may be appropriate, as these compounds seem to have a similar effect on glycated hemoglobin (HbA 1c ) compared with sulfonylureas or thiazolidinediones, but without the risk of hypoglycemia or weight gain [4] .
Linagliptin is a xanthine-based DPP-4 inhibitor that is now available in numerous countries worldwide for the treatment of type 2 diabetes mellitus (T2DM). Like most DPP-4 inhibitors, the pharmacological features of linagliptin permit once daily dosing, without the need for dose titration [5, 6] . However, unlike other DPP-4 inhibitors, the excretion of linagliptin is largely via the bile and gut and, therefore, dose adjustment is not required in patients with declining renal function [7, 8] .
Several clinical trials have demonstrated that linagliptin elicits reductions in HbA 1c , fasting plasma glucose (FPG), and postprandial glucose (PPG) in patients with T2DM [6, [9] [10] [11] [12] [13] .
The aim of the present study was to explore further the mechanisms underlying the improvements in glycemic control observed with linagliptin.
MATERIALS AND METHODS

Study Population
Patients aged between 18 and 80 years, with a body mass index of 40 kg/m 2 or less at screening, who were either treatment naive or had previously received monotherapy with oral antidiabetic agents and whose HbA 1c level was between 6.5% (C47.4 mmol/mol) and 10.0% (B85.8 mmol/mol) were eligible.
The main exclusion criteria included myocardial infarction, stroke, or transient ischemic attack within 6 months before enrollment; impaired hepatic function; renal insufficiency; hypersensitivity or allergy to linagliptin, sitagliptin, or excipients; or treatment with rosiglitazone, pioglitazone, GLP-1 analogs, insulin, DPP-4 inhibitors, or anti-obesity drugs during the previous 3 months. Plasma glucose was measured electrochemically with a biosensor-based assay (Super GL, Hitado, Möhnesee-Delecke, Germany). Intact GLP-1 was measured by a fluorescence-based enzyme-linked immunosorbent assay, using a Linco research system (Linco Research Inc., St Charles, MO, USA) instrument. Plasma DPP-4 levels were determined using a semiquantitative enzyme activity assay with fluorescence detection, which has been described previously [14] .
Levels of intact GIP and HbA 1c were measured as described previously [15] [16] [17] .
International Federation of Clinical Chemistry values for HbA 1c were converted from percentages to mmol/mol. Glucagon, insulin, and C-peptide levels were analyzed using specific immunoassays. Levels of fructosamine and 1,5-anhydroglucitol were measured using specific enzymatic assays.
Throughout the study, safety was assessed based on adverse event frequencies and severities, vital signs, 12-lead electrocardiogram, physical examination, and laboratory tests.
Endpoints
The primary assessments, after 28 days of treatment, were change from baseline in weighted mean glucose (WMG), and change For sample size estimation, the placeboadjusted change from baseline in WMG was assumed to be -17.2 mg/dL (0.95 mmol/L), with a SD of 22.6 mg/dL (1.25 mmol/L) (based on a study by Brazg et al. [18] ). Lower variability was assumed for the other primary endpoint, GLP-1 AUEC 0-2h . Based on these assumptions, 38 completers per treatment arm were needed to achieve a power of 90% for the change in WMG, whereas the power was greater than 98%
for GLP-1 AUEC 0-2h .
A per protocol set of patients was created for analyses of the primary and secondary endpoints to compare linagliptin with placebo. In addition, an exploratory analysis was performed using the data obtained from subjects receiving sitagliptin treatment. However, the trial was not designed or sufficiently powered to compare the efficacy or tolerability of linagliptin with sitagliptin.
RESULTS
Demographic and Baseline Characteristics
Demographic and baseline characteristics were similar across the patient groups. The mean (SD) baseline values for HbA 1c were 7.3% (0.53%), and for FPG were 9.25 (1.53) mmol/L. Diabetes medications used previously (67.8% of patients) were metformin (55.4%), sulfonylureas (9.1%), and glinides (3.3%). A total of 121 patients was randomly assigned (40 to placebo, 40 to linagliptin, and 41 to sitagliptin). Three patients (2.5%) withdrew from the study prematurely: two patients in the placebo arm who experienced hyperglycemia, and one patient in the linagliptin group for whom there was difficulty in obtaining blood samples. One subject in the placebo group had a protocol violation that was considered to be important during blinded review (incorrect timing of administration of trial medication).
The analysis of secondary, but not the primary, endpoints excluded this patient and was performed using data obtained from the 117 patients who completed the study without relevant protocol violations. Data on demographics, baseline characteristics, and safety were derived from the complete patient set (n = 121).
Primary and Secondary Endpoints
After 4 weeks of treatment, linagliptin elicited decreases in 24-h WMG and increases in GLP-1 AUEC 0-2h (Table 1) . These changes were significantly larger than those seen with placebo (P\0.0001 for all comparisons).
Likewise, linagliptin achieved significant placebo-corrected changes from baseline for FPG and for glucose AUEC 0-3h .
Inhibition of DPP-4
Median DPP-4 inhibition achieved by linagliptin treatment at trough was 79.8%
at day 2 (24 h after the first dose). DPP-4 inhibition by linagliptin was then sustained at 80% or greater throughout the treatment period. On day 28, median DPP-4 inhibition at trough was 82.2% for linagliptin and 70.3% for sitagliptin (estimate of median difference: 12.6%; 95% CI 9.5% to 15.7%; P\0.0001). Two weeks after the last dose of linagliptin to plasma DPP-4 was still inhibited by approximately 17%.
Effects on Incretins and Other Peptide Hormones
Linagliptin therapy increased placebo-corrected intact GIP AUEC 0-2h by approximately 1.5-fold on day 1 (from a baseline value of 129.9 ± 9.0 pmol/h) with approximately a two-fold increase observed on day 28 (Table 2) . Data for intact GLP-1 AUEC 0-2h on day 1 were in line with these data, showing increases of similar magnitude on days 1 and 28 (Tables 1 and  2 ). Placebo-corrected levels of glucagon decreased significantly on days 1 and 28 with linagliptin. For insulin and C-peptide, changes from baseline were not significant.
Following a MTT on day 28, mean plasma concentrations of intact GLP-1 increased in the linagliptin-treated group compared with placebo, at all time points evaluated (Fig. 1 ).
In line with these changes, mean plasma glucagon levels were reduced in the linagliptin-treated group versus placebo.
Effects on Plasma Glucose Parameters
The placebo-adjusted changes from baseline of plasma glucose parameters following linagliptin therapy were statistically significant on days 1 and 28, including 2-h PPG, peak glucose, glucose AUEC 0-3h , and 24-h WMG (Tables 1  and 2 ). For FPG, the placebo-adjusted change from baseline was not significant on day 1 but reached statistical significance on day 28.
Placebo-adjusted means for HbA 1c showed a nonsignificant reduction on day 15 and significant reductions on days 28 (Table 2) and 42 (-0.28%; 95% CI -0.42 to -0.13;
Fructosamine showed a significant reduction from baseline on day 28, but not on day 15 of treatment (Table 2) or at 2 weeks posttreatment (day 42) (-5.1 lmol/L; 95% CI -16.8 to 6.5; P = 0.3848). There were significant increases from baseline in 1,5-anhydroglucitol levels on days 15 and 28 (Table 2 ), but at 2 weeks post-treatment (day 42) the increase was not statistically significant (0.8 lg/mL; 95% CI -1.0 to 2.6; P = 0.3634). The 24-h glucose profile, evaluated on day 28, showed that linagliptin was associated with lower mean plasma glucose concentrations at all time points, compared with placebo ( Fig. 1) .
Results obtained on days 29/30 were essentially similar; therefore, only data from day 28 are presented.
Exploratory Analyses: Linagliptin versus Sitagliptin
Additional exploratory sensitivity analyses, including all three study treatments, compared P-value -\0.0001
AUEC area under the time-effect curve, CI confidence interval, FPG fasting plasma glucose, GLP-1 glucagon-like peptide-1, SE standard error, WMG weighted mean glucose 
Data shown are adjusted mean change from baseline * FPG measured on day 2 -no data available AUEC area under the time-effect curve, CI confidence interval, FPG fasting plasma glucose, GIP glucose-dependent insulinotropic polypeptide, GLP-1 glucagon-like peptide-1, HbA 1c glycated hemoglobin, IFCC international federation of clinical chemistry, PPG postprandial glucose, SE standard error, WMG weighted mean glucose P = 0.2230), respectively. None of the observed differences between linagliptin and sitagliptin, for primary and secondary endpoints, were statistically significant.
Safety and Tolerability
The safety analysis comprised 121 patients who had received at least one dose of trial medication. Forty-three patients (35.5%) experienced at least one adverse event during the study (Table 3) . However, most adverse events were mild and there were no severe or serious adverse events; no adverse events led to treatment discontinuation. During the washout phase, one patient experienced two severe adverse events that were not considered to be treatment related (aggravated migraine and a panic attack that required hospitalization). 
DISCUSSION
This study provides the most detailed comparison to date of the acute and longerterm effects of linagliptin on glycemic control in patients with insufficiently controlled T2DM. In this study, orally administered linagliptin, 5 mg once daily, significantly improved 24-h glycemic control compared with placebo, as indicated by a reduction in plasma WMG levels.
Twenty-four hours after the first dose of linagliptin, median DPP-4 inhibition was approximately 80%, which has previously been proposed as the threshold for effective glycemic control [19] . Inhibition of DPP-4 was sustained throughout the 4-week study, with a low level (17%) detectable even 2 weeks after the end of linagliptin administration. These findings are consistent with stable binding of linagliptin to DPP-4 and the long terminal halflife of the drug (128-184 h in healthy individuals) [14] .
In accordance with these findings, linagliptin improved HbA 1c levels and longer-term markers of glycemic control, i.e., fructosamine and 1,5-anhydroglucitol levels. The effect on HbA 1c was maintained 2 weeks after treatment cessation. As 1,5-anhydroglucitol competes with glucose for renal tubular reabsorption [20] , it gives a better reflection of postmeal glycemic excursions than HbA 1c or fructosamine [21, 22] . Indeed, in this study, linagliptin primarily reduced PPG levels rather than FPG; FPG was virtually unchanged 24 h after the first dose and moderately reduced (a decrease of approximately 6% vs. baseline) after 4 weeks. In contrast, after 4 weeks of linagliptin administration, the change from baseline in plasma glucose 2 h after MTT (PPG) was 2.4 mmol/L (a decrease of approximately 15%). As the patients in this study had reasonably good glycemic control (mean baseline HbA 1c was 7.30 ± 0.53%), this may be a result of the glucose-dependent blood glucoselowering effect that has been observed with DPP-4 inhibitors in general [3] .
Medium-term markers of glycemic control might be more appropriate than HbA 1c to evaluate the potential of linagliptin to improve blood glucose control in a study with a 4-week treatment duration. Nevertheless, It is well established that glucagon secretion exhibits characteristic abnormalities in T2DM. Frequently, patients have fasting hyperglucagonemia and exaggerated responses to meal tests [25] . GLP-1 is an inhibitor of glucagon secretion and also retains this ability in patients with T2DM [26] . It has recently been suggested that the clinical importance of the GLP-1-induced insulin stimulation and glucagon inhibition contribute equally to the glucose-lowering effect of GLP-1 in patients with T2DM [27] . Therefore, it is fair to assume that both the significant increase in GLP-1 and the decrease in glucagon levels accounted for the glucose-lowering potential of linagliptin in this study.
Importantly, GLP-1 elevation by DPP-4 inhibitors does not impair the counterregulatory response of glucagon to hypoglycemia [28] .
Furthermore, linagliptin is associated with a negligible risk of hypoglycemia when administered as monotherapy. Indeed, no patient developed symptomatic hypoglycemia while receiving either of the DPP-4 inhibitors in this study, confirming the low risk observed in previous studies [6, 9, 14, [29] [30] [31] .
The absence of any significant effects of linagliptin administration on insulin and C-peptide peak excursion or AUEC 0-2h indicate that insulin levels are maintained despite a concomitant reduction in glucose levels. This suggests improved responsiveness of the pancreatic beta cells to glucose levels and an insulinotropic effect. It is important to note that GLP-1-mediated insulin secretion is glucosedependent and, as linagliptin reduced both the peak excursion and AUEC 0-3h of glucose within 1 day, the interpretation of insulin and C-peptide data may need to take this into account. This presumably explains why no changes in insulin and C-peptide have been observed, and is in accordance with previous studies that did not find treatment-related changes in absolute fasting and postprandial insulin levels or in C-peptide levels [18, 32] . 
